Odanacatib for the treatment of postmenopausal osteoporosis: results of the LOFT multicentre, randomised, double-blind, placebo-controlled trial and LOFT Extension studyMichael R. McClung, Jean‐Yves Reginster, Jose Adolfo Rodriguez-Portales et al.|The Lancet Diabetes & Endocrinology|2019Cited by 171
Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosisPierre D. Delmas, Steven Boonen, Michael R. McClung et al.|Bone|2007Cited by 97
Monthly dosing of 75 mg risedronate on 2 consecutive days a month: efficacy and safety resultsPierre D. Delmas, Michael R. McClung, C.L. Benhamou et al.|Osteoporosis International|2007Cited by 68
Efficacy and safety of risedronate 150-mg once a month in the treatment of postmenopausal osteoporosis: 2-year dataMichael R. McClung, P. D. Delmas, José Zanchetta et al.|Osteoporosis International|2012Cited by 31
A Novel Monthly Dosing Regimen of Risedronate for the Treatment of Postmenopausal Osteoporosis: 2-Year DataMichael R. McClung, Pierre D. Delmas, Claude-Laurent Benhamou et al.|Calcified Tissue International|2012Cited by 10